Aled Edwards, the CEO of the Structural Genomics Consortium, tells the Globe and Mail that it makes no sense for pharmaceutical scientists at different organizations to be working on the same problems. "The semiconductor industry in the '80s started to collaborate with one another on the platform," Edwards says. "They said: Every one of us generating a unique platform on which to build our hardware is silly, right?
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.